Ataxia Telangiectasia in a Patient with Breast Cancer: A Case Report.

Q3 Medicine
Mari Mizuno, Yuko Ohnuki, Ai Unzaki, Mizuho Suzuki, Kei Takeshita, Saori Takahashi, Hikaru Kiyohara, Saeko Nakagawa, Rie Ishida, Kozue Yokoyama, Mayako Terao, Takuho Okamura, Toru Hanamura, Naoki Niikura
{"title":"Ataxia Telangiectasia in a Patient with Breast Cancer: A Case Report.","authors":"Mari Mizuno,&nbsp;Yuko Ohnuki,&nbsp;Ai Unzaki,&nbsp;Mizuho Suzuki,&nbsp;Kei Takeshita,&nbsp;Saori Takahashi,&nbsp;Hikaru Kiyohara,&nbsp;Saeko Nakagawa,&nbsp;Rie Ishida,&nbsp;Kozue Yokoyama,&nbsp;Mayako Terao,&nbsp;Takuho Okamura,&nbsp;Toru Hanamura,&nbsp;Naoki Niikura","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Ataxia telangiectasia (AT) is a rare autosomal recessive disorder caused by the pathological variants of the <i>ATM</i> gene. Owing to i ts r arity a nd n ature, complications of AT, such a s malignant tumors, a re often difficult to manage with standard imaging studies and treatments, and there are no established management strategies. We report the case of a woman who had AT in childhood and developed breast cancer in her 20s; the disease was successfully managed by the decision-making of multidisciplinary physicians professionals with ethics support. She was immunocompromised, ataxic, and mentally impaired. The patient's mother noticed a tumor in her right breast and subsequently brought her to our department. Although preoperative testing and surgical procedures were limited as AT is extremely radiosensitive, the patient was diagnosed with cT2N0M0 breast cancer and underwent right mastectomy and axillary lymph node sampling. The final diagnosis was pT2N0M0 pStage IIA mucinous carcinoma, and immunohistochemistry of the tumor specimen was estrogen receptor-positive, progesterone receptor-positive, and HER2-negative. Tamoxifen was administered as postoperative adjuvant therapy, and the patient has survived to date without recurrence. Here, we report our experience with breast cancer treatment for AT, along with a review of the literature.</p>","PeriodicalId":38819,"journal":{"name":"Tokai Journal of Experimental and Clinical Medicine","volume":"48 3","pages":"95-98"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tokai Journal of Experimental and Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Ataxia telangiectasia (AT) is a rare autosomal recessive disorder caused by the pathological variants of the ATM gene. Owing to i ts r arity a nd n ature, complications of AT, such a s malignant tumors, a re often difficult to manage with standard imaging studies and treatments, and there are no established management strategies. We report the case of a woman who had AT in childhood and developed breast cancer in her 20s; the disease was successfully managed by the decision-making of multidisciplinary physicians professionals with ethics support. She was immunocompromised, ataxic, and mentally impaired. The patient's mother noticed a tumor in her right breast and subsequently brought her to our department. Although preoperative testing and surgical procedures were limited as AT is extremely radiosensitive, the patient was diagnosed with cT2N0M0 breast cancer and underwent right mastectomy and axillary lymph node sampling. The final diagnosis was pT2N0M0 pStage IIA mucinous carcinoma, and immunohistochemistry of the tumor specimen was estrogen receptor-positive, progesterone receptor-positive, and HER2-negative. Tamoxifen was administered as postoperative adjuvant therapy, and the patient has survived to date without recurrence. Here, we report our experience with breast cancer treatment for AT, along with a review of the literature.

乳腺癌患者共济失调性毛细血管扩张1例报告。
共济失调毛细血管扩张症(AT)是一种罕见的常染色体隐性遗传病,由ATM基因的病理变异引起。由于它的特殊性和复杂性,其并发症,如恶性肿瘤,通常难以通过标准的影像学检查和治疗来管理,并且没有既定的管理策略。我们报告了一名妇女,她在童年时期患有AT,并在20多岁时发展为乳腺癌;该疾病在多学科医师专业人员的决策和道德支持下得到了成功的管理。她免疫功能低下,共济失调,智力受损。病人的母亲发现她的右乳房有肿瘤,随后带她来我科。尽管由于AT对放射极其敏感,术前检查和手术治疗受到限制,但患者被诊断为cT2N0M0乳腺癌,并接受了右侧乳房切除术和腋窝淋巴结取样。最终诊断为pT2N0M0 pStage IIA粘液癌,肿瘤标本免疫组化雌激素受体阳性,孕激素受体阳性,her2阴性。他莫昔芬作为术后辅助治疗,患者存活至今无复发。在这里,我们报告了我们治疗乳腺癌AT的经验,并回顾了文献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
32
期刊介绍: The Tokai Journal of Experimental and Clinical Medicine, also referred to as Tokai Journal, is an official quarterly publication of the Tokai Medical Association. Tokai Journal publishes original articles that deal with issues of clinical, experimental, socioeconomic, cultural and/or historical importance to medical science and related fields. Manuscripts may be submitted as full-length Original Articles or Brief Communications. Tokai Journal also publishes reviews and symposium proceedings. Articles accepted for publication in Tokai Journal cannot be reproduced elsewhere without written permission from the Tokai Medical Association. In addition, Tokai Journal will not be held responsible for the opinions of the authors expressed in the published articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信